Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 14/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093282 | 0.92 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL11955075 | 0.90 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL15140566 | 0.87 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL23222355 | 0.87 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL13519706 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL10089216 | 0.86 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL458148 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL21553751 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL11955156 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL458805 | 0.85 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2023-01-24 | — | — | US | disclosed |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2022-01-04 | — | — | US | disclosed |
| US-11026930-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-06-08 | — | — | US | disclosed |
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-10940139-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-03-09 | — | — | US | disclosed |
| US-10933054-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-03-02 | — | — | US | disclosed |
| US-20090124653-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| US-7498440-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2009-03-03 | — | — | US | disclosed |
| US-7498440-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2009-03-03 | — | — | US | disclosed |
| US-7488827-B2 | Muscle relaxants; respiratory system disorders; asthma;COPD; emphysema; bronchitis | GLAXO GROUP LIMITED (GB) | 2009-02-10 | — | — | US | disclosed |
| US-7488827-B2 | Muscle relaxants; respiratory system disorders; asthma;COPD; emphysema; bronchitis | GLAXO GROUP LIMITED (GB) | 2009-02-10 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| US-20070249664-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-25 | — | — | US | disclosed |
| US-20070249664-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-25 | — | — | US | disclosed |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249664-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | SMN1; SMN2 2627/4885NPC1 2708/4885RAB9A 2952/4885 |
| US-20090124653-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | SMN1; SMN2 2627/4885NPC1 2708/4885RAB9A 2952/4885 |
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | SMN1; SMN2 3555/4885NPC1 2606/4885RAB9A 36/4885 |
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | SMN1; SMN2 4331/4885NPC1 2024/4885RAB9A 2641/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | SMN1; SMN2 4331/4885NPC1 2024/4885RAB9A 2641/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | SMN1; SMN2 4859/4885NPC1 8/4885RAB9A 4272/4885 |
| US-10940139-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | SMN1; SMN2 3555/4885NPC1 2606/4885RAB9A 36/4885 |
| US-11026930-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | SMN1; SMN2 3555/4885NPC1 2606/4885RAB9A 36/4885 |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | SMN1; SMN2 3555/4885NPC1 2606/4885RAB9A 36/4885 |
| US-10933054-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | SMN1; SMN2 3555/4885NPC1 2606/4885RAB9A 36/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | SMN1; SMN2 3555/4885NPC1 2606/4885RAB9A 36/4885 |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | CHRM3, CHRNG, CHRM2 | SMN1; SMN2 2627/4885NPC1 2708/4885RAB9A 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.